Abstract
Background We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer’s disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
Methods This longitudinal cohort study involved 140 patients (50 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (CSF, amyloid-PET, and 18F-FDG-PET) at baseline. They were rated according to the A/T/N system and followed up for a mean time of 2.72±0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty-eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements after two years after baseline.
Results At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (AUC=0.82). We identified cut-off value of
19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (p-SCD), and 14 MCI patients developed AD dementia (p-MCI). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% C.I.=65.69:94.31]). The rate of NfL change was higher in p-MCI (3.52±4.06 pg/mL) compared to np-SCD (0.81±1.25 pg/mL) and np-MCI (−0.13±3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC=0.954).
Conclusion Plasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.
Key messages
What is already known on this topic
Plasma NfL increase in SCD, MCI and AD and longitudinal changes in NfL are related to changes in brain atrophy and cognitive outcomes in AD. Nevertheless, the clinical value of plasma NfL in non-demented patients has been poorly explored.
What this study adds
Plasma NfL accurately predicts AD pathology and progression of cognitive decline in SCD and MCI. Repeated measurements of NfL may further increase the accuracy of this biomarker
How this study might affect research, practice, or policy
Given its accessibility, blood-based NfL can assist clinicians in determining the optimal personalized diagnostic and therapeutic approach for individuals presenting with SCD or MCI, providing insights into the underlying biological mechanisms of cognitive decline, even in primary care settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT05569083
Funding Statement
This project was funded by Tuscany Region - PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With machine learning - PREVIEW - CUP. D18D20001300002
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study procedures and data analysis were performed in accordance with the Declaration of Helsinki and with the ethical standards of the Committee on Human Experimentation of our Institute. This study was approved by the Institutional Review Board of Careggi University Hospital (Florence, Italy, reference 15691oss). All individuals involved in this research agreed to participate and to have details and results of the research about them published.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This project was funded by Tuscany Region - PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer’s Disease With machine learning - PREVIEW - CUP. D18D20001300002
Disclosures: authors have no disclosures relevant to this study
Data Availability
All data produced in the present study are available upon reasonable request to the authors
